Fostemsavir / 5mg
Properties
| Signal Word | Warning |
| Density | 1.60±0.1 g/cm3 |
| Boiling Point | 904.1±75.0 °C |
Product Description
Fostemsavir is a novel antiretroviral medication designed to treat HIV-1 infection, particularly in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection. It is the first attachment inhibitor approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for this purpose. Fostemsavir works by inhibiting the attachment of HIV-1 to host cell CD4 receptors, a crucial step in the virus's replication process. This is achieved through its active metabolite, temsavir, which specifically binds to the gp120 subunit of the HIV-1 envelope glycoprotein, adjacent to the gp120-CD4 binding site. This binding prevents the conformational change required for HIV-1 to attach to the host cell, thereby inhibiting the virus's entry and replication.
Articles:
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Judith A. Aberg, Bronagh Shepherd, Marcia Wang, Jose V. Madruga, Fernando Mendo Urbina, Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy N. Kumar, Eduardo Sprinz, Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade & Allan R. Tenorio
https://doi.org/10.1007/s40121-023-00870-6
- Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir
Publication Date: 11 March 2020
Yagai Bouba, Giulia Berno, Lavinia Fabeni, Luca Carioti, Romina Salpini, Stefano Aquaro, Valentina Svicher, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Maria Mercedes Santoro
https://doi.org/10.1093/jac/dkaa073
- Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
Publication Date: 06 February 2020
Chakradhar Lagishetty, Katy Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee